The company said treatment did not improve motor function among boys aged 4 to 7 years in the study, called Ciffreo and an important test of the therapy’s potential.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,